Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

LianBio - ADR
Healthcare
P/NCAV
0.15x
Ticker
LIANY
Exchange
Over The Counter
Country
United States
Close
0.28 $
Mkt Cap
30.5M $
EV
-72.9M $
NCAV Burn Rate
19.6%
Current Ratio
10.06
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
0.6x
EV/FCF
0.7x
Dilution
0.8% p.A
Total Net Income
-470.5M $
Cheapness
100.0%
LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average